Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02829918 · ClinicalTrials.gov registry record · Phase 2
Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
A Phase 2 study of Biliary Tract Cancer and Biliary Tract Neoplasms, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
- 3
- Study locations
NCT02829918 is a Phase 2 study of Biliary Tract Cancer and Biliary Tract Neoplasms that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 54 participants, below the 238-participant average among 36 other Biliary Tract Cancer trials with a reported enrollment target (77% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT02829918, a Phase 2 study of Biliary Tract Cancer and Biliary Tract Neoplasms, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
- 3
- Study locations
Study Summary
This research study is designed to see if a drug called Nivolumab is effective in treating patients with advanced refractory biliary tract cancers. Nivolumab has been approved by the U.S. Food and Drug Administration (FDA) for treatment of certain types of cancer but is not approved by the FDA for treatment of your type of cancer.
Conditions Studied
Interventions
- DRUG Nivolumab
Study Locations (3)
California
- City of Hope Cancer Center - Duarte
Florida
- H. Lee Moffitt Cancer Center and Research Institute - Tampa
Georgia
- Emory University Winship Cancer Institute - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2016-10-05 |
| Est. Completion | 2023-05-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02829918
The ClinicalTrials.gov registry entry for NCT02829918 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 238-participant average among 36 other Biliary Tract Cancer trials with a reported enrollment target (77% lower). The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Biliary Tract Cancer appearing as the primary indexed condition, and to 1 intervention - of which Nivolumab is the first listed.
NCT02829918 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT02829918 about?
NCT02829918 is a clinical study titled "Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers". This research study is designed to see if a drug called Nivolumab is effective in treating patients with advanced refractory biliary tract cancers. Nivolumab has been approved by the U.S. Food and Drug Administration (FDA) for treatment of certain types of cancer but is not approved by the FDA for t...
What is the current status of trial NCT02829918?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2016-10-05. Estimated completion is 2023-05-24.
What conditions does trial NCT02829918 study?
This clinical trial studies the following conditions: Biliary Tract Cancer, Biliary Tract Neoplasms.
What interventions are being tested in trial NCT02829918?
The interventions under investigation include: Nivolumab (DRUG).
Who is sponsoring clinical trial NCT02829918?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02829918 being conducted?
This trial has 3 study locations across California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Biliary Tract Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
RECRUITING · Phase 2
-
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
RECRUITING · Phase 2
-
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
RECRUITING · Phase 2
-
Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
RECRUITING · Phase 2
-
Ligufalimab and Cadonilimab in Advanced Liver Cancers
RECRUITING · Phase 2
-
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.